These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. Camponovo F; Ockenhouse CF; Lee C; Penny MA BMC Infect Dis; 2019 Oct; 19(1):920. PubMed ID: 31664924 [TBL] [Abstract][Full Text] [Related]
3. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. Thompson HA; Hogan AB; Walker PGT; Winskill P; Zongo I; Sagara I; Tinto H; Ouedraogo JB; Dicko A; Chandramohan D; Greenwood B; Cairns M; Ghani AC Lancet Glob Health; 2022 Dec; 10(12):e1782-e1792. PubMed ID: 36400084 [TBL] [Abstract][Full Text] [Related]
4. Development and Evaluation of a Cryopreserved Whole-Parasite Vaccine in a Rodent Model of Blood-Stage Malaria. Stanisic DI; Ho MF; Nevagi R; Cooper E; Walton M; Islam MT; Hussein WM; Skwarczynski M; Toth I; Good MF mBio; 2021 Oct; 12(5):e0265721. PubMed ID: 34663097 [TBL] [Abstract][Full Text] [Related]
5. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01 Chandramohan D; Dicko A; Zongo I; Sagara I; Cairns M; Kuepfer I; Diarra M; Tapily A; Issiaka D; Sanogo K; Mahamar A; Sompougdou F; Yerbanga S; Thera I; Milligan P; Tinto H; Ofori-Anyinam O; Ouedraogo JB; Greenwood B BMJ Open; 2020 Sep; 10(9):e035433. PubMed ID: 32933955 [TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
7. Malaria vaccines: past, present and future. von Seidlein L; Bejon P Arch Dis Child; 2013 Dec; 98(12):981-5. PubMed ID: 24061779 [TBL] [Abstract][Full Text] [Related]
8. Vaccines against malaria-still a long way to go. Matuschewski K FEBS J; 2017 Aug; 284(16):2560-2568. PubMed ID: 28500775 [TBL] [Abstract][Full Text] [Related]
9. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. Theisen M; Jore MM; Sauerwein R Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178 [TBL] [Abstract][Full Text] [Related]
10. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission. Brooks A; Briët OJ; Hardy D; Steketee R; Smith TA PLoS One; 2012; 7(3):e32587. PubMed ID: 22412892 [TBL] [Abstract][Full Text] [Related]
11. The march toward malaria vaccines. Hoffman SL; Vekemans J; Richie TL; Duffy PE Vaccine; 2015 Nov; 33 Suppl 4(Suppl 4):D13-23. PubMed ID: 26324116 [TBL] [Abstract][Full Text] [Related]
18. Malaria Elimination: Time to Target All Species. Lover AA; Baird JK; Gosling R; Price RN Am J Trop Med Hyg; 2018 Jul; 99(1):17-23. PubMed ID: 29761762 [TBL] [Abstract][Full Text] [Related]
19. Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis. Topazian HM; Schmit N; Gerard-Ursin I; Charles GD; Thompson H; Ghani AC; Winskill P Vaccine; 2023 May; 41(20):3215-3223. PubMed ID: 37080831 [TBL] [Abstract][Full Text] [Related]
20. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. Ghani AC; Sutherland CJ; Riley EM; Drakeley CJ; Griffin JT; Gosling RD; Filipe JA PLoS One; 2009; 4(2):e4383. PubMed ID: 19198649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]